France· FR:63572267
EXBLIFEP 2 g/0,5 g, poudre pour solution à diluer pour perfusion
A medicinal product containing enmétazobactam + dichlorhydrate de céfépime monohydraté, registered in France by ADVANZ PHARMA LIMITED.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ENMÉTAZOBACTAM + DICHLORHYDRATE DE CÉFÉPIME MONOHYDRATÉ
- Manufacturer
- ADVANZ PHARMA LIMITED
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip13340093029722310 flacon(s) en verre de 20 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Enmétazobactam + dichlorhydrate de céfépime monohydraté in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEXBLIFEPADVANZ PHARMA Limited, Dublin
- SpainEXBLIFEP 2 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAdvanz Pharma Limited
- FinlandEXBLIFEPAdvanz Pharma Limited
- United KingdomExblifep 2g/0.5g powder for concentrate for solution for infusion vialsAdvanz Pharma
- IrelandEXBLIFEP 2 g/0.5 g powder for concentrate for solution for infusionAdvanz Pharma Limited
- IcelandEXBLIFEPADVANZ PHARMA Limited
- NetherlandsEXBLIFEP 2 g/0,5 g, poeder voor concentraat voor oplossing voor infusieAdvanz Pharma Limited
- NorwayExblifepAdvanz Pharma Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Exblifep
- Liechtenstein · Exblifep
- Norway · Exblifep
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0a1d4e14-808b-4297-b152-5dc036159ab8 GET /v1/drugs/0a1d4e14-808b-4297-b152-5dc036159ab8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63572267",
"date_amm": "2024-03-21",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/24/1794",
"substance": "ENMÉTAZOBACTAM + DICHLORHYDRATE DE CÉFÉPIME MONOHYDRATÉ",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about enmétazobactam + dichlorhydrate de céfépime monohydraté.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.